Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era
Main Authors: | Lucia Gandini, Gabriele Fior, Andreas Schibler, Nchafatso G. Obonyo, Gianluigi Li Bassi, Jacky Y. Suen, John F. Fraser |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | Critical Care |
Online Access: | https://doi.org/10.1186/s13054-023-04394-w |
Similar Items
-
Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies
by: Bairbre A. McNicholas, et al.
Published: (2023-01-01) -
Correction : Epidemiology and outcomes of early-onset AKI in COVID-19-related ARDS in comparison with non-COVID-19-related ARDS: insights from two prospective global cohort studies
by: Bairbre A. McNicholas, et al.
Published: (2023-05-01) -
The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?
by: Karin Wildi, et al.
Published: (2021-01-01) -
Correction to: The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?
by: Karin Wildi, et al.
Published: (2021-02-01) -
ECMO use in COVID-19: lessons from past respiratory virus outbreaks—a narrative review
by: Hwa Jin Cho, et al.
Published: (2020-06-01)